We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
7 own
7 watching
Current Price
$0.66
$0.06
(9.98%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
17.14M
52-Week High
6.08
52-Week Low
0.49
Average Volume
0.02M
Dividend Yield
--
P/E Ratio
--
Market Capitalization17.14M
52-Week High6.08
52-Week Low0.49
Average Volume0.02M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company s lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Globe Newswire
3days ago
ANDOVER, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate ...
Globe Newswire
8days ago
ONCR-719 is uniquely engineered to use the Epidermal Growth Factor Receptor (EGFR/EGFRvIII) for viral entry, which is highly expressed in glioblastoma multiforme (GBM); data show that the canonical entry receptor for HSV-1, NECTIN-1, is only minimally expressed in human GBM tumors. ONCR-719 ...
Globe Newswire
1month ago
New preclinical results support self-amplifying vRNA/LNP immunotherapy platform and ongoing IND-enabling studies of ONCR-021ANDOVER, Mass., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on stimulating the immune system to transform outcomes ...
Globe Newswire
7 months ago
ONCR-021 and ONCR-788 demonstrate robust preclinical anti-tumor efficacy following IV-administration vRNA Immunotherapy Platform has the potential to address challenges associated with IV-administered RNA-based oncology therapeutics Oncorus is advancing ONCR-021 into clinical development, with IND ...
Zolmax
8 months ago
HC Wainwright assumed coverage on shares of Oncorus (NASDAQ:ONCR Get Rating) in a research report released on Monday morning, The Fly reports. The brokerage issued a buy rating and a $7.00 target price on the stock. A number of other analysts have also commented on the company. Zacks Investment ...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$0.66
$0.06
(9.98%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00